A spanish biotech company

TECHNOLOGICAL PLATFORM OF DISRUPTIVE DRUGS BASED ON PEPTIDES TO FIGHT AMYLOID-RELATED DISEASES.

Our Mission

Provide the phama industry with excellent medicines for amyloid-related diseases, including post-traumatic stress disorder and degenerative diseases such as Type 2 diabetes, Parkinson disease and ALS.

Our Vision

We want to contribute to a better World by helping patiens to prevent, treat and cure amyloid-related diseases through disruptive technological solutions.

Check Our Research Studies

Innovating in the next generation of drugs for prevention, treatment, and cure of AMYLOID-RELATED DISEASES.

Post-Traumatic Stress Disorder

Type 2 diabetes

Parkinson's disease

Amyotrophic lateral sclerosis

About us

TECHNOLOGICAL PLATFORM OF DISRUPTIVE DRUGS BASED ON PEPTIDES TO FIGHT AMYLOID-RELATED DISEASES

DisruPep S.L. was born in 2020 as a spanish biotech with technology for the development of peptide-based drugs. DisruPep is a spin-off Technology-Based Company of the Cajal Institute in Madrid with an important laboratory of neuroscience. The Cajal Institute is the oldest institute from the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC), which is the largest public institution dedicated to research in Spain and the third largest in Europe. DisruPep was originally created with the purpose of developing and exploiting a patent license for a drug candidate for post-traumatic stress disorder: the QBP1 peptide. Currently, the company develops also other drugs and products of of high biomedical interest.

Why Choose Us

The company builts up on the accumulated knowledge of more than a decade of research of the laboratory of Dr. Carrión Vázquez working, in the field of amyloid diseases. We have the challenge of developing drugs to the help millions of people who suffer from those diseases by developing disruptive medicines directed to therapeutic targets placed at the start of the amyloid cascade.

Post-traumatic stress disorder (PTSD)

Parkinson's disease

Type 2 diabetes

Amyotrophic lateral sclerosis (ALS)

The Impact Our Research

PTSD

0 ^%

population

0 ^%

of prevalence. Sexual aggression, víctims of terrorism, traffic accidents, natural disasters:

Parkinson

0 ^%

population > 60

0 ^%

> 80 y The number of PD patients is expected to double by 2030.

Diabetes Mellitus 2

0 ^%

among adults aged 20 to 79

0 ^%

The total number is expected to increase to 643 million (11.3%) in 2030 and 783 million (12.2%) in 2045.

ASL

0 ^cases

per 100,000 people. It has no treatment and is rapidly degenerative.

MARKET SIZE:

TAM 1.970 M € /year

MARKET SIZE:

is expected to be worth US$ 5.41 Billion in 2023.

Market size:

US$ 35 billion in 2023. Expected to surpass around US$ 61.6 billion by 2030

Market size:

$662.3 million in 2022, and is projected to reach $1,038.94 million by 2032.

Our Expert Team

Company with Technological Base (EBT), Spin-Off from CSIC